An autoimmune upstart turns PD-L1 around to blaze a new approach to diabetes, multiple sclerosis
PD-L1 has become one of the most familiar targets in the global cancer research world, a key player in mediating a coordinated immune system assault on cancer cells.
But what if you could also turn it around, use elevated PD-L1 to muffle an autoimmune response by T cells, hitting the brakes on the immune system and avoiding an assault on healthy tissue — rather than taking your foot off the brake and targeting cancerous cells?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.